LP-10 (Intravesical)
Hemorrhagic Cystitis
Phase 2aActive - Positive results published, Orphan Drug Designation
Key Facts
Indication
Hemorrhagic Cystitis
Phase
Phase 2a
Status
Active - Positive results published, Orphan Drug Designation
Company
About Lipella Pharmaceuticals
Lipella Pharmaceuticals leverages its proprietary liposomal delivery platform to develop targeted therapies for mucosal diseases where traditional treatments struggle. The company has a diversified pipeline with LP-10 in Phase 2 trials for oral lichen planus, hemorrhagic cystitis, and oral graft-versus-host disease, and LP-50 in preclinical development for bladder cancer. Their strategy focuses on repurposing proven drugs through the 505(b)(2) regulatory pathway to accelerate development and reduce risk.
View full company profile